<h4>Background</h4>The purpose of our study was to assess the effect of sodium-glucose cotransporter protein 2 (SGLT-2) inhibitors on the progression of liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD), which is currently renamed metabolic dysfunction-associated steatohepatitis (MASLD).<h4>Methods</h4>From database establishment to February 2025, we systematically searched electronic databases, including PubMed, Web of Science, Embase, and the Cochrane Library, to identify relevant randomized controlled trials (RCTs). Here, SLC5A2 is linked to Hepatic fibrosis.